Previous 10 | Next 10 |
2023-04-25 09:04:56 ET TRACON Pharmaceuticals ( TCON ) -51% after I-Mab gets favorable ruling in arbitration. Appreciate Holdings ( SFR ) -26% . First Republic Bank ( FRC ) -22% after Q1 earning release . Netcapital ( NCPL ) -22% . T...
2023-04-25 09:02:39 ET The US FDA has granted Orphan Drug designation to IN8bio's ( NASDAQ: INAB ) INB-400 and INB-410 to treat several types of glioma. Both are gamma-delta T cell therapies intended to initially treat glioblastoma multiform, a type of brain cancer. Pa...
First-ever orphan drug designation for genetically modified gamma-delta T cell therapies This orphan drug designation offers potential 7-year market exclusivity for both autologous (INB-400) and allogeneic (INB-410) candidates INB-400 is an autologous, genetically engineer...
IN8bio, Inc. (NASDAQ: INAB) is one of today's top gainers. The company's shares are currently up 173.33% on the day to $2.87. IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of ...
2023-04-24 10:15:18 ET IN8bio ( NASDAQ: INAB ) stock rose ~110% on Monday after the company reported data from a phase 1 trial of INB-100 in patients with leukemia. The company said that data showed that 100% of evaluable patients (n=7) on INB-100 remained alive, progre...
2023-04-24 10:08:54 ET Gainers: IN8bio ( INAB ) +121% . IDEAYA Biosciences ( IDYA ) +27% . ZyVersa Therapeutics ( ZVSA ) +26% . Koninklijke Philips ( PHG ) +15% . Kiora Pharmaceuticals ( KPRX ) +9% . Losers: Scilex H...
INB-100 treatment has achieved durable 100% complete remission (CR) in treated patients, including high-risk acute myeloid leukemia (AML) patients and a patient with acute lymphoblastic leukemia (ALL) who had failed 4 prior lines of therapy, including CAR-T, with all evaluable patients remaining ...
INB-300, a gamma-delta T cell chimeric antigen receptor (CAR) platform, demonstrated the ability to target cancer cells while sparing healthy tissue when both express the CAR-targeted antigen. CAR platform leverages the ability of gamma-delta T cells to selectively target tumor cells su...
2023-04-11 09:02:57 ET Nano-cap biotech IN8bio ( NASDAQ: INAB ) added ~7% pre-market Tuesday after announcing that new data from its Phase 1 trial for allogeneic cell therapy candidate INB-100 will be presented at a medical event in Europe later this month. An allogeneic, ...
Updated data on durability of responses and long-term complete responses (CRs) in leukemia patients treated with INB-100 will be presented; no dose-limiting toxicities have been observed New correlative data on immune reconstitution and gamma-delta T cell proliferation for Cohorts 1 a...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc . (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and Co-founder, will participate in a fireside chat during the H.C. Wainwrigh...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 1.8% to $131.88 on volume of 307,014,213 shares SRIVARU Holding Limited (SVMH) rose 49.2% to $0.2275 on volume of 274,465,266 shares Nauticus Robotics Inc. (KITT) rose 19.6% to $0.192 on volume of 161,46...
A look at the top 10 most actives in the United States SRIVARU Holding Limited (SVMH) rose 94.8% to $0.2971 on volume of 77,516,058 shares NVIDIA Corporation (NVDA) fell 0.3% to $129.16 on volume of 39,120,242 shares Longeveron Inc. (LGVN) rose 27.0% to $3.415 on volume of 36,214,736 shar...